Obesity-drug price and channel fight
Eli Lilly launched its oral obesity pill Foundayo while Novo Nordisk rolled out a subscription programme for Wegovy and pushed a high-dose Wegovy HD through more than 70,000 pharmacies—setting up a pricing, format and distribution battle. At the same time, cheap generic semaglutide copies from India are already pressuring branded sales, which could speed moves toward broader access and shifting employer/insurer cost dynamics. (biopharmadive.com), (managedhealthcareexecutive.com), (bloomberg.com)
A weight-loss drug war that used to be about who had the best weekly shot is turning into a fight over three simpler things: pill versus injection, subscription versus list price, and direct delivery versus pharmacy shelves. Eli Lilly put its new pill Foundayo on the US market on April 10, while Novo Nordisk spent the prior week widening access to Wegovy through telehealth subscriptions and a broader pharmacy push. (biopharmadive.com) (managedhealthcareexecutive.com) Lilly’s new product is Foundayo, the brand name for orforglipron, a glucagon-like peptide 1 pill. Glucagon-like peptide 1 drugs copy a gut hormone that tells the brain and stomach to slow eating, so patients feel full sooner and longer. (prnewswire.com) The pitch for Foundayo is convenience. Lilly says it is the only glucagon-like peptide 1 pill for weight loss that can be taken any time of day without food or water restrictions, which removes the routine that comes with older oral drugs. (prnewswire.com) Price is the second front. Lilly said Foundayo will start at $25 a month for commercially insured patients and $149 for self-pay patients through LillyDirect, its own online pharmacy channel with home delivery. (prnewswire.com) (biopharmadive.com) Novo answered with a different play. On March 31, Novo launched a multi-month Wegovy subscription for eligible self-pay patients through Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame listed as coming later. (managedhealthcareexecutive.com) (prnewswire.com) Novo says that program can save up to $1,200 a year on injectable Wegovy and up to $600 a year on oral Wegovy. The company is using telehealth partners as the storefront, which means it is not only selling a drug but also bundling the doctor visit, prescription, and refill path into one channel. (managedhealthcareexecutive.com) (prnewswire.com) Novo is also leaning on old-fashioned pharmacy reach. Reports this week said the company is pushing a higher-dose Wegovy HD through more than 70,000 pharmacies, which gives it a shelf-and-distribution advantage while Lilly is steering early Foundayo demand into LillyDirect. (finance.yahoo.com) That channel fight matters because obesity drugs are expensive enough that many employers and insurers still limit coverage. If drugmakers can make monthly costs more predictable with subscriptions, coupons, or direct fulfillment, they have a better shot at keeping patients on treatment long enough for buyers to justify paying. (fiercehealthcare.com) (managedhealthcareexecutive.com) There is another pressure point outside the United States. In India, semaglutide patents have expired, cheap copies are flooding the market, and Bloomberg reported on April 9 that Lilly’s share in the local glucagon-like peptide 1 market was already slipping as lower-cost versions spread. (bloomberg.com) (cnbc.com) CNBC, citing Pharmarack data, said Lilly’s share in India fell to 56% in March from 61% in February, while Novo held at 25%. That is an early look at what happens when a blockbuster obesity ingredient stops being scarce and starts being priced like a commodity. (cnbc.com) So the next phase of this market is not just a science race. It is a retail race in which Lilly is betting that a flexible pill plus direct shipping can pull patients in, while Novo is betting that subscriptions, telehealth partners, and mass pharmacy presence can keep Wegovy in front. (biopharmadive.com) (managedhealthcareexecutive.com)
